Business Wire

OH-FORGE-BIOLOGICS

20.9.2021 14:02:44 CEST | Business Wire | Press release

Share
Forge Biologics Announces Regulatory Updates from FDA and EMA, Accelerating Manufacturing and Clinical Trial Momentum

Forge Biologics, a gene therapy-focused contract development and manufacturing organization, today announced that it has received additional designations and regulatory feedback from the European Medicines Agency (EMA) and the U.S. Food & Drug Administration (FDA), advancing the manufacturing capabilities for its own and clients’ AAV gene therapies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210920005324/en/

The EMA has granted orphan designation for the company’s clinical-stage gene therapy FBX-101 for the treatment of patients with Krabbe disease. FBX-101 is a first-in-human potential treatment utilizing a systemically administered adeno-associated virus (AAV) to deliver the correct version of the faulty gene responsible for an abnormality in patients with Krabbe disease, a rare and fatal genetic disorder. FBX-101 previously received Orphan Drug and Rare Pediatric Disease Designations from the FDA earlier this year.

“FBX-101 is the culmination of over 20 years of scientific research to understand the challenges faced by patients with progressive disease after hematopoietic stem cell transplantation, the current standard of care,” said Maria Escolar, M.D., Forge’s Chief Medical Officer. “We are currently recruiting patients for our RESKUE clinical trial to administer FBX-101 and we are pleased by the EMA’s designation so that patients in Europe may also have access to this potentially transformative therapeutic approach.”

The company also announced that the FDA has provided positive feedback on Forge’s AAV manufacturing processes, including use of its exclusive production plasmids and master cell bank for cGMP manufacturing of gene therapies.

Forge presented information to the FDA on its proprietary HEK293 suspension cell line, Ignition Cells™, and adenovirus helper plasmid, pEMBR™, and received FDA alignment that these technologies are suitable for cGMP manufacturing of clinical drug products.

“We are excited that the tools we have developed at Forge will help accelerate and scale cGMP production of AAV gene therapies for patients. We are thankful to have a positive dialogue with the EMA and for gaining alignment with the FDA on the suitability of our key production materials for our own and our clients’ use,” said Christopher Shilling, Vice President of Regulatory Affairs and Quality. “These new technologies can help mitigate current safety concerns surrounding critical raw materials used in AAV scale-up and production processes for programs moving from research to clinical stage.”

Forge offers “concept to clinic” AAV manufacturing and development services to accelerate gene therapy programs from preclinical stage through clinical with technology platforms enabling fully traceable cell line history for potential commercialization.

About Krabbe Disease

Krabbe disease is a rare, pediatric leukodystrophy affecting about 1-2.5 in 100,000 people in the U.S. and is inherited in an autosomal recessive manner. Krabbe disease is caused by loss-of-function mutations in the galactosylceramidase (GALC) gene, a lysosomal enzyme responsible for the breakdown of certain types of lipids such as psychosine. Without functional GALC, psychosine accumulates to toxic levels in cells. The psychosine toxicity is most severe in the myelin cells surrounding the nerves in the brain and in the peripheral nervous system, eventually leading to the death of these cells. The disease initially manifests as physical delays in development, muscle weakness and irritability and advances rapidly to difficulty swallowing, breathing and cognitive problems, and vision and hearing loss. Early onset or “Infantile” Krabbe disease cases usually results in death of patients by age 2-4 years, while later onset or “Late Infantile” cases have a more variable course of progressive decline. There is currently no approved treatment for Krabbe disease.

About FBX-101

Forge developed FBX-101 to treat patients with Infantile Krabbe disease. FBX-101 is an adeno-associated viral (AAV) gene therapy that is typically delivered after a hematopoietic stem cell transplant. FBX-101 delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system. FBX-101 has been shown to functionally correct the central and peripheral neuropathy and correct the behavioral impairments associated with Krabbe disease in animal models, as well as to drastically improve lifespan in animal models of the disease. This approach has the potential to overcome some of the immunological safety challenges observed in traditional AAV gene therapies.

About Orphan Designation

EMA orphan designation is designed to encourage the development of new treatments for life-threatening or chronically debilitating conditions that are rare (affecting not more than five in 10,000 people in the European Union). Medicines like FBX-101 that meet the EMA’s orphan designation criteria qualify for several incentives, including extended market exclusivity, protocol assistance, and potentially reduced fees for regulatory activities. The orphan designation is issued by the EMA Committee for Orphan Medicinal Products (COMP) for use in the European Union.

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea into reality. Forge has a 175,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most.

For more information, please visit https://www.forgebiologics.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/forgebiologics

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

teamLab Biovortex Kyoto to Open 'Teahouse in a Sea of Light' for Savoring Tea. On View from Friday, November 20. Artworks Including Tea in Spontaneous Order on View20.11.2026 07:00:00 CET | Press release

teamLab Biovortex Kyoto opens ‘Teahouse in a Sea of Light’ on Friday, November 20, 2026, where visitors can savor tea within the Sea of Solidified Light. Artworks exhibited in the teahouse, including Tea in Spontaneous Order, are now unveiled. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117922442/en/ Aged Coffee Tonic, Tea in Spontaneous Order, 2021- ©︎ teamLab *Shot in real space. No AI or CGI. *No Artificial Colors Teahouse in a Sea of Light A space for savoring tea within a sea of light. When a cup of tea is made, the artwork is born. The tea interacts with nearby tea and the sea of light, creating a time structure throughout the entire space of the artwork. Visitors drink part of this formed order itself. Coinciding with the opening of ‘Teahouse in a Sea of Light,’ Pocket Garden of Eternal Existence is newly unveiled at the museum's entrance gate. teamLab Biovortex Kyoto teamLab Biovortex Kyoto is teamLab's largest

OCP Announces Date of Third Quarter and Nine-Month 2026 Earnings19.11.2026 17:30:00 CET | Press release

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its third quarter and nine-month 2026 results on Monday, November 30, 2026. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 7:00 a.m. EDT, 12:00 p.m. Morocco and London time (GMT). OCP senior management will host a conference call to discuss third quarter and nine-month 2026 results at 8:00 a.m. EDT, 1:00 p.m. Morocco and London time (GMT) on Monday, November 30, 2026, for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma. About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s production history. OCP has exclusive ac

ISACA Launches Updated COBIT 7 With Enhanced Assessment Model and Modern Digital Platform19.11.2026 16:24:00 CET | Press release

Refreshed framework reflects today’s technology landscape with streamlined design guidance, refreshed objectives and three levels of organizational assessment When AI can spark fears about humanity’s future and aging technology can bring air travel to a standstill, the cost of weak governance is impossible to ignore. To help enterprises strengthen the governance of their information and technology, ISACA has launched COBIT 7, an updated version of its globally recognized framework for information and technology (I&T) governance. Built for a rapidly changing digital world, the new COBIT 7 framework combines trusted guidance, an intuitive digital platform, customizable resources, and practical tools to help practitioners turn technology into measurable value, align decisions with strategy and confidently navigate emerging risks, including AI. COBIT 7 reinforces the framework’s longstanding role in helping businesses align their I&T operations with broader strategic goals, manage technolo

North Star Carbon Removal Project Selected by Government of Canada for Landmark Carbon Removal Procurement Program19.11.2026 16:04:00 CET | Press release

Microsoft-backed Saskatchewan project developed by MLTC and Svante among only three BECCS projects selected North Star, a planned large-scale carbon dioxide removal (CDR) project being developed by Meadow Lake Tribal Council (MLTC) and Svante Technologies Inc. (Svante), has been selected by the Government of Canada as a qualified supplier under the federal Request for Standing Offer (RFSO) for the Acquisition and Retirement of Credits from Carbon Dioxide Removal Projects. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261118228180/en/ The proposed North Star bioenergy with carbon capture and storage project is being developed by the Meadow Lake Tribal Council (MLTC) and Svante. The project will generate durable carbon dioxide removal credits by capturing biogenic CO2 from the MLTC Bioenergy Center in Meadow Lake, SK, Canada, and storing it deep underground in a geological storage site. North Star was one of only three bioene

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press release

Developers Can Now Reach Players on Desktop and the Web With Xsolla Player and Xsolla Pages Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally req

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye